Blonde L, Raccah D, Lew E, Meyers J, Nikonova E, Ajmera M, Davis KL, Bertolini M, Guerci B. Treatment intensification in type 2 diabetes: a real world study of 2-OAD regimens, GLP-1 RAx, or basal insulin. Diabetes Ther. 2018 Jun;9(3):1169-84. doi: 10.1007/s13300-018-0429-x
Mansfield C, Sikirica MV, Pugh A, Poulos CM, Unmuessig V, Morano R, Martin AA. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017 Dec;8(6):1365-78. doi: 10.1007/s13300-017-0326-8
Nagar SP, Patel A, Bali V, Aparasu RR. Prevalence and predictors of pediatric depression in the United States. Int J Pharm Sci Nanotech. 2014 Sep;7(3):91-7.
Nagar SP, Mhatre S, Hatfeild MD, Aparasu RR. Patterns and predictors of antipsychotic usage among U.S. adults: a national co-morbidity survey replication study. Int J Pharm Sci Nanotech. 2014 Apr;7(2):52-68.
Poulos C, González JM, Lee LJ, Boye KS, Johnson FR, Bae JP, Deeg MA. Physician preferences for extra-glycemic effects of type 2 diabetes treatments. Diabetes Ther. 2013 Dec;4(2):443-59. doi: 10.1007/s13300-013-0046-7.
Primatesta P, Plana Hortoneda E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord. 2011 May 20;12:103. doi: 10.1186/1471-2474-12-103
Rothman KJ, Wepsic JG. Side of facial pain in trigeminal neuralgia. J Neurosurg. 1974 Jan 1;40(4):514-6.